Navigation Links
Adherence course reduces hypertension
Date:2/16/2011

A high proportion of patients with high blood pressure are failing to take their medication properly and would benefit clinically from a course of 'adherence therapy', according to new research from the University of East Anglia (UEA).

High blood pressure or hypertension is one of the major cardiovascular diseases worldwide. It leads to stroke and heart disease and costs more than $300 billion each year. Around a quarter of the adult population is affected including 10 million people in the UK.

Around half of patients with hypertension fail to reduce their blood pressure because they are not taking their prescribed medication correctly. Some cease taking their medication altogether, others only take some of it, and others do not follow the instructions to take their medicine after food, for example.

The reasons for this non-adherence are complex and include ambivalence about taking drugs, concerns over side effects, and complexity of treatement regimes. Previous attempts to improve adherence with information leaflets, monthly outpatient visits, reminders and self-monitoring have been shown to be mostly ineffective.

The UEA resesarchers studied 136 patients with high blood pressure in three outpatient clinics in Jordan. Half were given a course of seven weekly 'adherence therapy' sessions and half continued with their usual treatment. The 20-minute face-to-face sessions allowed a trained clinician to provide tailored information about the illness and treatment, and explore the patient's individual beliefs, fears and lifestyle.

Published today in the Journal of Human Hypertension, the results show that the patients given adherence therapy took 97 per cent of their medications (compared with only 71 per cent for those given treatment as usual) and, on average, reduced their blood pressure by around 14 per cent taking it to just above the healthy range.

Lead author Prof Richard Gray of UEA's School of Nursing and Midwifery said: "Our findings suggest a clear clinical benefit in these patient-centred sessions.

"High blood pressure affects millions of people in both the developed and developing world and the problem is likely to increase dramatically over the next 15 years. Tackling the widespread failure to take medication correctly would lead to a major reduction in stroke and heart disease.

"If adherence therapy were a new drug it would be hailed as a potentially major advance in hypertension treatment."

Adherence therapy was originally developed by Prof Gray for patients with mental health problems who failed to take their medication correctly. The total cost of delivering a course of seven weekly sessions is calucated to be approximately 80 per person. Although the UEA study was not designed to formally evaulate cost effectiveness, other studies predict that a long-term reduction of blood pressure would lead to a reduction in stroke of 56 per cent and a reduction in chronic heart disease of 37 per cent suggesting that adherence therapy would likely be a cost-effective intervention.


'/>"/>

Contact: Simon Dunford
s.dunford@uea.ac.uk
44-160-359-2203
University of East Anglia
Source:Eurekalert

Related medicine news :

1. Side effects of hormonal breast cancer therapy increased; may affect treatment adherence
2. Medication adherence improves blood pressure control in chronic kidney disease
3. Adherence to practice guidelines may reduce bleeding in cirrhosis patients
4. Electronic Monitoring of Asthma Med Use May Boost Adherence
5. NACDS RxIMPACT "Hill Day" Features More Advocates Increased Focus on Medication Adherence
6. Clinically Relevant Technologies Releases New Medical iPhone App To Fill Gap In Adherence To Low Back Pain Management Guidelines
7. NHGRI charts course for the next phase of genomics research
8. CTO summit and left main coronary interventions course will feature latest research and techniques
9. CTO Summit & Left Main Coronary Interventions Course to be held Feb. 14-16, 2011, in NYC
10. Strong scientific findings presented at AIDS 2010 point to promise ahead and underscore the need to stay the course
11. Atlanta School of Sleep Medicine Offers Physician Board Review Course in October 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... , ... October 12, 2017 , ... IsoComforter, Inc. ( ... announced today the introduction of an innovative new design of the shoulder pad. ... you get maximum comfort while controlling your pain while using cold therapy. By utilizing ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... that we intend to develop to enable prevention of a major side effect ... hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed ...
(Date:10/12/2017)... D.C. (PRWEB) , ... October 12, 2017 , ... Leading ... their peers in Washington, D.C., for the 49th Congress of the International Society ... ., Vice President of the Center for Cancer and Blood Disorders at ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... the nation's first interactive health literacy software tool, and the Cancer Patient Education ... of cancer patient education, today announce a new strategic alliance. , As ...
(Date:10/12/2017)... ... October 12, 2017 , ... Farm Forward joins ... other leading institutions in announcing the launch of the Leadership Circle , ... animals are raised for food. , Founding members of the Leadership Circle also ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... Oct. 11, 2017  Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: ... facility in Las Piedras, Puerto Rico ... blades. Following ... facility sustained minor structural damage, temporary loss of power ... have been completed, manufacturing operations have resumed, and the ...
(Date:10/4/2017)... South Korea , Oct. 4, 2017  South ... its next-generation CPR training aide "cprCUBE" on Kickstarter. The ... chest compression during cardiac arrests with better efficiency compared ... It also offers real-time feedback on efficacy of the ... The crowdfunding campaign has a goal to raise $5,000. ...
(Date:10/2/2017)... -- AllianceRx Walgreens Prime, the combined central specialty pharmacy and ... manager Prime Therapeutics LLC (Prime), today officially began the ... of new signage at its headquarters in ... few other company-owned facilities across the country. This also ... whom will begin to see the AllianceRx Walgreens Prime ...
Breaking Medicine Technology: